WBUR 90.9 FM, Sept. 22, 2017
Stock in the Cambridge pharmaceutical company, Alnylam, is soaring due to expectations it may have successfully tested a so-called “RNAI” drug that could treat a rare malfunction of the nervous system. Luke Timmerman, who writes the bio-tech newsletter “The Timmerman Report,” joined Morning Edition.
WBUR 90.9 FM, July. 10, 2017
It’s been a relatively slow year for the U.S. biotech sector. So far, only 16 companies nationwide have gone public since January.
That’s about half as many as during the boom years between 2013 and 2015.
But the last couple of weeks have seen four IPOs, including two here in Massachusetts, for the firms Mersana and Aileron. Both are focused on cancer drugs.
For a look at the dry spell, and what might be driving the possible shift underway, we spoke to Luke Timmerman, founder and editor of the biotech industry newsletter the Timmerman Report.
KUOW 94.9, Sept. 21, 2015
Jeannie Yandel talks to Luke Timmerman of the Timmerman Report about Chris Rivera’s tenure as President of the Washington Biotechnology And Biomedical Association.
KUOW 94.9, Jul. 31, 2015
Marcie Sillman talks to Luke Timmerman, founder and editor of the Timmerman Report, about Juno Therapeutics and other biotech startups like Just Biotherapeutics that came out of the closure of Amgen’s Seattle offices last year.